| Website | prospectventures.com |
| Phone | 650-327-8800 |
| Employees |
| Health-Care Fund IV, 8/10 | $180M |
Prospect Venture Partners is a Palo Alto, California based venture capital firm with over $1B of capital under management. The firm is dedicated to investing in outstanding biopharmaceutical and medical device companies. Prospect targets commercially attractive biomedical enterprises with outstanding entrepreneurial management teams, proprietary products, and innovative technologies with the potential for significant investment returns.
The firm invests in companies with a wide variety of development and financing requirements including new company incubations, first and second venture financing rounds, and later stage private and public companies with proven business models requiring expansion capital.
Prospect Venture Partners seeks to ultimately invest $10-$20 million in each company as a lead investor or as a co-lead in an investor syndicate. First round investments generally range from $500,000 to $10 million. Prospect Venture Partners typically has representation on the board of each of its portfolio companies, and serves as an active partner.
| Company | Date | Round | Size | Participants |
| SentreHEART | 6/12 | Series C | $26M | 3 |
| Satori Pharmaceuticals | 2/12 | Venture Round | $15M | 3 |
| DFine | 11/11 | Venture Round | $25M | 5 |
| Topica Pharmaceuticals | 10/11 | Series B | $27M | 3 |
| Azelon Pharmaceuticals | 10/11 | Series A | $4.5M | 3 |
| Kythera Biopharmaceuticals | 9/11 | Series D | $37.4M | 7 |
| SurePoint Medical | 1/11 | Venture Round | 1 | |
| NinePoint Medical | 10/10 | Series A | $33M | 2 |
| Pathwork Diagnostics | 10/10 | Series C | $30M | 6 |
| Complete Genomics | 8/10 | Series E | $39M | 7 |
| DFine | 7/10 | Venture Round | $36.2M | 4 |
| Baxano | 6/10 | Series C | $30M | 6 |
| NGM Biopharmaceuticals | 3/10 | Series B | $51M | 3 |
| Neomend | 1/10 | Series D | $30M | 5 |
| DFine | 1/10 | Venture Round | $2.8M | 4 |
| Lux Biosciences | 10/09 | Series B | $50M | 4 |
| Alvine Pharmaceuticals | 9/09 | Series A | $21.5M | 6 |
| Gloucester Pharmaceuticals | 8/09 | Series D | $29M | 5 |
| Complete Genomics | 8/09 | Series D | $45M | 6 |
| Visiogen | 5/09 | Series D | $40M | 7 |
| Satori Pharmaceuticals | 1/09 | Series A | $22M | 4 |
| DFine | 1/09 | Venture Round | $35M | 4 |
| Kythera Biopharmaceuticals | 5/08 | Series C | $30M | 9 |
| NGM Biopharmaceuticals | 2/08 | Series A | $24.6M | 3 |
| Cogentus Pharmaceuticals | 12/07 | Series C | $62.5M | 4 |
| Roxro Pharma | 6/07 | Series B | $42.7M | 3 |
| Alvine Pharmaceuticals | 9/06 | Series A | $8M | 2 |
| Kythera Biopharmaceuticals | 7/06 | Series B | $30M | 6 |
| Pathwork Diagnostics | 7/06 | Venture Round | $11M | 5 |
| nanosys | 11/05 | Series D | $41.5M | 16 |
| Allux Medical | 8/05 | Venture Round | $6.4M | 3 |
